PHP16 ASSESSMENT OF DECISION MAKER NEEDS RELATED TO HEALTH ECONOMIC MODELS AND DATA ANALYSIS TOOLS  by Olson, BM et al.
PHP14
GENERIC PRESCRIPTION MEDICINES PRICEVARIATION
AMONG COMMUNITY PHARMACIES, PUBLIC HOSPITAL
PHARMACIES AND DISPENSING DOCTORS IN ZIMBABWE
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OBJECTIVES: To evaluate generic medicine price variation
among private retail pharmacies, public hospital pharmacies and
dispensing doctors in institutions in different provinces in Zim-
babwe. To compare prices of drugs on the Essential drugs list of
Zimbabwe (EDLIZ) and those not on the list and prices of
imported versus locally produced medicines. METHODS: Using
a standardized WHO and Health Action International (HAI)
methodology and data collection form, we collected medicine
price data for 58 institutions (comprising 27 community phar-
macies, eight public pharmacies and 23 dispensing doctors) on
37 carefully selected and commonly used generic medicines. At
each institution, we identiﬁed and recorded the price of the least
price generic medicine. The study was done in ﬁve of the ten
provinces in the country. We used a computerised WHO/HAI
International Medicine Price Workbook for data analysis.
RESULTS: Of the 37 generic medications, 18 and 22 were
signiﬁcantly expensive in dispensing doctors than in community
pharmacies and public hospital pharmacies respectively
(p < 0.05). Price of generic medications were not signiﬁcantly
different across provinces (p > 0.05). EDLIZ drugs had higher
overall mean prices than non-EDLIZ drugs (t = 2.274, df = 35;
p = 0.029). This was true in all the three sectors surveyed. There
was no signiﬁcant difference in overall mean drug prices between
locally produced medicines and imported medicines (t = -1.313;
df = 34; p = 0.197). Medications with high prices in the private
sector also had high prices in the public sector (r = 0.98,
p < 0.001). CONCLUSION: Zimbabwean generic medications’
prices are high and vary widely across sectors and by status of the
drug (EDLIZ vs. non-EDLIZ drugs). This may have differential
impacts on affordability and clinical outcomes.
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PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN
SOUTH KOREA USING DISCRETE CHOICE EXPERIMENTS
Lim MK, Bae EY
Health Insurance Review Agency, Seoul, Seocho-Gu, South Korea
OBJECTIVES: The purpose of this study was to elicit preferences
for drug listing decision criteria in South Korea using the discrete
choice experiment (DCE) method. METHODS: A DCE survey
questionnaire was administered to a sample of respondents who
were educated in the principle concepts of pharmacoeconomics
and are decision makers or stakeholders within that ﬁeld. To
develop choice designs, we ﬁrst decided on the attributes and
levels through literature review and discussion with experts who
are involved in the decision making process. Then orthogonal
and balanced designs were determined using a computer algo-
rithm. A total of 15 choice sets were produced from the afore-
mentioned process. With the addition of 2 test questions, subjects
were shown a total of 17 sets of drugs with different levels of
ICER, uncertainty, budget impact, and severity of disease. We
used the conditional logit model to assess the effects of each
attribute. RESULTS: Parameter estimates from the model indi-
cate that all attributes inﬂuenced respondent’s choice signiﬁ-
cantly and each parameter has an expected sign. The Lower the
ICER, the higher the probability of choosing that alternative.
Respondents also preferred low levels of uncertainty and a
smaller impact on health service budget, and were likely to
choose drugs for serious diseases rather than mild or moderate
ones. We also found that those in our sample were willing to
accept high ICER to get medication for severe diseases. CON-
CLUSION: This study demonstrates that the cost-effectiveness,
budget impact and severity of disease are the main reimburse-
ment decision criteria in South Korea, and that DCE can be a
useful tool in analyzing the decision making process where a
variety of factors are considered and prioritized.
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OBJECTIVES: The objective of this study was to gather infor-
mation from individuals involved in the decision-making process
for determining the value of health care interventions.
METHODS: In April 2007, health care decision makers from
organizations across the US were invited to participate in a focus
group discussion. Prior to the focus group, participants com-
pleted a questionnaire, which inquired about the challenges
and/or opportunities associated with using health economic and
outcomes research information in the decision-making process.
RESULTS: Nine individuals with an average of over 14 years
experience, representing major managed care and pharmacy
beneﬁt management organizations, the Veteran’s Affairs Depart-
ment, and Academia participated. The three most challenging
issues to health care decision makers included: 1) ﬁltering
through all the information needed to determine value; 2) agree-
ing with the key assumptions used in models and/or research
reports; and 3) accepting model projections as an accurate reﬂec-
tion of outcomes that may be seen in their own patient popula-
tions. Findings revealed that decision makers are looking for
more customization, more applicability to their own organiza-
tions, and increased transparency when reviewing outcomes
research and/or health economic models. Other key ﬁndings
included, decision maker interest in being involved in the devel-
opment of tools and models from early phases, maximizing the
user-friendly aspect of models (without compromising transpar-
ency), development of tools that help decision makers analyze
real-world data, and the need for education and training as an
essential component of successful implementation of health eco-
nomic models and tools. CONCLUSION: This investigation
gives critical insight into how future health economic and out-
comes research models and data analysis tools should be devel-
oped. As payer needs continue to evolve, so must the models and
analysis tools that are developed, especially if they are expected
to continue to be used in the decision-making process.
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RECOMMENDATIONS FROM REIMBURSEMENT AGENCIES
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OBJECTIVES: There is increased interest in post-launch eco-
nomic studies as more jurisdictions require economic data for the
formal decision process of pricing and reimbursement of drugs.
METHODS: We reviewed all of the ﬁnal recommendations
regarding all pharmaceutical submissions to the CDR from its
inception in May 2004 through January 2007. Decisions were
categorised as: listed, listed with criteria or not listed. Recom-
mendations for further research post-launch were reviewed and
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